Reduction of Negative Charge in Mercaptoacetyl-Based Chelators Influences the Biodistribution of Prostate-Specific Membrane Antigen-Targeting Pseudopeptides Labeled with Technetium-99m; ACS Pharmacology & Translational Science; Vol. 8, iss. 10
| Parent link: | ACS Pharmacology & Translational Science.— .— Washington: ACS Publications Vol. 8, iss. 10.— 2025.— P. 3600-3612 |
|---|---|
| その他の著者: | , , , , |
| 要約: | Title screen Prostate cancer (PCa) is the most common cancer and the second leading cause of death among men worldwide. Significant progress has been made in managing PCa by targeting the prostate-specific membrane antigen (PSMA), which holds great promise for improving the accuracy and effectiveness of diagnosis. Previously, we reported a high-affinity glutamate–urea–lysine (EuK)-based PSMA-targeting tracer, BQ0413, containing the maE3 chelator for labeling with technetium-99m for single-photon emission tomography diagnostic imaging. BQ0413 demonstrated efficient tumor targeting in PCa patients with concomitant elevated activity retention in the kidneys, which is typical for EuK-based PSMA-targeting tracers. We hypothesized that a decrease in the tracer’s total negative charge, by substituting negatively charged glutamate residues in the maE3 chelator with polar neutral serine, could decrease activity retention in the kidneys. The present study aimed to evaluate the tumor targeting and biodistribution profile of two new PSMA-targeting tracers, BQ0500 (maESE) and BQ0501 (maS3), in comparison to BQ0413 (maE3). Conjugates were successfully radiolabeled with technetium-99m and characterized in vitro and in vivo. [99mTc]Tc-BQ0500 and [99mTc]Tc-BQ0501 demonstrated PSMA-specific binding to PC3-pip cells with picomolar affinity; however, the affinity was 3–5-fold compromised in comparison with the reference [99mTc]Tc-BQ0413. Full replacement of glutamate residues by serines in [99mTc]Tc-BQ0501 resulted in an improved overall clearance from normal organs with a moderately increased accumulation of activity in the gastrointestinal tract. [99mTc]Tc-BQ0501 demonstrated efficient tumor targeting and improved tumor-to-background ratios. These results suggest that chelator modifications, such as charge alteration, play a critical role in improving tumor targeting and pharmacokinetics for EuK-based PSMA-targeting tracers Текстовый файл |
| 言語: | 英語 |
| 出版事項: |
2025
|
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1021/acsptsci.5c00428 |
| フォーマット: | 電子媒体 図書の章 |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=683112 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 683112 | ||
| 005 | 20251114151322.0 | ||
| 090 | |a 683112 | ||
| 100 | |a 20251114d2025 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 102 | |a US | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i |b e | |
| 182 | 0 | |a b | |
| 183 | 0 | |a cr |2 RDAcarrier | |
| 200 | 1 | |a Reduction of Negative Charge in Mercaptoacetyl-Based Chelators Influences the Biodistribution of Prostate-Specific Membrane Antigen-Targeting Pseudopeptides Labeled with Technetium-99m |f Ekaterina Bezverkhniaia, Panagiotis Kanellopoulos, Ulrika Rosenström [et al.] | |
| 203 | |a Текст |b визуальный |c электронный | ||
| 283 | |a online_resource |2 RDAcarrier | ||
| 300 | |a Title screen | ||
| 320 | |a References: 40 tit | ||
| 330 | |a Prostate cancer (PCa) is the most common cancer and the second leading cause of death among men worldwide. Significant progress has been made in managing PCa by targeting the prostate-specific membrane antigen (PSMA), which holds great promise for improving the accuracy and effectiveness of diagnosis. Previously, we reported a high-affinity glutamate–urea–lysine (EuK)-based PSMA-targeting tracer, BQ0413, containing the maE3 chelator for labeling with technetium-99m for single-photon emission tomography diagnostic imaging. BQ0413 demonstrated efficient tumor targeting in PCa patients with concomitant elevated activity retention in the kidneys, which is typical for EuK-based PSMA-targeting tracers. We hypothesized that a decrease in the tracer’s total negative charge, by substituting negatively charged glutamate residues in the maE3 chelator with polar neutral serine, could decrease activity retention in the kidneys. The present study aimed to evaluate the tumor targeting and biodistribution profile of two new PSMA-targeting tracers, BQ0500 (maESE) and BQ0501 (maS3), in comparison to BQ0413 (maE3). Conjugates were successfully radiolabeled with technetium-99m and characterized in vitro and in vivo. [99mTc]Tc-BQ0500 and [99mTc]Tc-BQ0501 demonstrated PSMA-specific binding to PC3-pip cells with picomolar affinity; however, the affinity was 3–5-fold compromised in comparison with the reference [99mTc]Tc-BQ0413. Full replacement of glutamate residues by serines in [99mTc]Tc-BQ0501 resulted in an improved overall clearance from normal organs with a moderately increased accumulation of activity in the gastrointestinal tract. [99mTc]Tc-BQ0501 demonstrated efficient tumor targeting and improved tumor-to-background ratios. These results suggest that chelator modifications, such as charge alteration, play a critical role in improving tumor targeting and pharmacokinetics for EuK-based PSMA-targeting tracers | ||
| 336 | |a Текстовый файл | ||
| 461 | 1 | |t ACS Pharmacology & Translational Science |c Washington |n ACS Publications | |
| 463 | 1 | |t Vol. 8, iss. 10 |v P. 3600-3612 |d 2025 | |
| 610 | 1 | |a prostate cancer | |
| 610 | 1 | |a prostate specific membrane antigen | |
| 610 | 1 | |a technetium-99m | |
| 610 | 1 | |a mercaptoacetyl-based chelator | |
| 610 | 1 | |a amino acid chains | |
| 610 | 1 | |a BQ0500 | |
| 610 | 1 | |a BQ0501 | |
| 610 | 1 | |a BQ0413 | |
| 610 | 1 | |a single-photon emission computed tomography | |
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 701 | 1 | |a Bezverkhniaia |b E. A. |c pharmacist |c Research Engineer Tomsk Polytechnic University |f 1994- |g Ekaterina Aleksandrovna |9 22467 | |
| 701 | 1 | |a Kanellopoulos |b P. |g Panagiotis | |
| 701 | 1 | |a Rosenstrom |b U. |g Ulrik | |
| 701 | 1 | |a Tolmachev |b V. M. |c specialist in the field of medical technology |c Director of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D |f 1961- |g Vladimir Maksimilianovich |9 22210 | |
| 701 | 1 | |a Orlova |b A. M. |c specialist in the field of medical technology |c Senior Researcher, Oncoteranostika Research Center, Tomsk Polytechnic University, Ph.D |f 1960- |g Anna Markovna |9 22212 | |
| 801 | 0 | |a RU |b 63413507 |c 20251114 | |
| 850 | |a 63413507 | ||
| 856 | 4 | |u https://doi.org/10.1021/acsptsci.5c00428 |z https://doi.org/10.1021/acsptsci.5c00428 | |
| 942 | |c CF | ||